NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) and MacroGenics (NASDAQ:MGNX – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.
Risk & Volatility
NewAmsterdam Pharma has a beta of 0.1, suggesting that its share price is 90% less volatile than the S&P 500. Comparatively, MacroGenics has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings for NewAmsterdam Pharma and MacroGenics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NewAmsterdam Pharma | 1 | 1 | 9 | 1 | 2.83 |
| MacroGenics | 1 | 3 | 2 | 0 | 2.17 |
NewAmsterdam Pharma presently has a consensus price target of $48.90, indicating a potential upside of 127.46%. MacroGenics has a consensus price target of $6.33, indicating a potential upside of 81.57%. Given NewAmsterdam Pharma’s stronger consensus rating and higher probable upside, research analysts plainly believe NewAmsterdam Pharma is more favorable than MacroGenics.
Profitability
This table compares NewAmsterdam Pharma and MacroGenics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NewAmsterdam Pharma | -3,644.21% | -34.81% | -31.50% |
| MacroGenics | -8.70% | -109.26% | -18.70% |
Institutional & Insider Ownership
89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 13.6% of MacroGenics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares NewAmsterdam Pharma and MacroGenics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NewAmsterdam Pharma | $22.50 million | 114.22 | -$203.82 million | ($2.16) | -9.95 |
| MacroGenics | $149.50 million | 1.49 | -$74.62 million | ($0.22) | -15.85 |
MacroGenics has higher revenue and earnings than NewAmsterdam Pharma. MacroGenics is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
MacroGenics beats NewAmsterdam Pharma on 8 of the 15 factors compared between the two stocks.
About NewAmsterdam Pharma
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
About MacroGenics
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
